Dr. Phillip Bendick, Preeminent Vascular Sonographer Joins CVR Medical
Vancouver, British Columbia--(Newsfile Corp. - August 22, 2017) - CVR Medical Corp. (TSXV: CVM) (FSE: B3BN) (OTCQB: CRRVF) ("CVR Medical") is pleased to announce the addition of Dr. Phillip J. Bendick, PhD, to the company's advisory staff. Dr. Bendick, a renowned medical sonographer and researcher, will assist CVR in the organization of expanded clinical trials for the "Carotid Stenotic Scan (CSS)" device.
Dr. Bendick will bring a wealth of knowledge and an extensive network to CVR. Since 1971, he has worked, taught, and presented at medical institutions across the world, making seminal contributions to the field of vascular sonography. He has served on the Board of Governors of the American Institute of Ultrasound in Medicine (AIUM), among many other prestigious appointments, and has authored over 150 peer-reviewed articles, 15 book chapters and, most recently, held the position of Editor-in-Chief emeritus of the Journal of Diagnostic Medical Sonography.
"My goal with CVR is to help prove their technology as effective and efficient," Dr. Bendick says. "I'll be working to establish additional clinical sites for the CSS, in order to gather as much data as possible that can be correlated with ultrasound and other, more invasive, imaging techniques."
CVR CEO Peter Bakema states, "We're thrilled to have Dr. Bendick's incredible insight going forward in this process. It really speaks volumes for the technology and product we've developed that someone of his stature in the industry, with so much experience with the existing models, would join us in this revolutionary effort."
Wasting no time in becoming part of that effort, Dr. Bendick has already put forth inquiries on behalf of CVR to some of the nation's leading research facilities.
"I've spent 40 years using ultrasound to diagnose carotid disease," he tells. "I've seen how good it is, but I've also seen all its pitfalls and problems. It takes a long time, it is extremely operator-dependent; [the CSS device] offers the ability to do this very simply in about five minutes. For both diagnostic and research results, it has the potential to do really great things."
As much as he, and CVR, are focused on changing the past practices of vascular sonography with this contemporary advancement, he admits just as much excitement in looking ahead. "CVR is going to validate this technology, and then I think we'll see huge opportunities open up. I talk to doctors about this who can look down the road and see how this device could impact their fields of expertise. This stage is truly the very tip of the iceberg."
For additional information on the organization, leadership, and current news please visit the company website at www.CVRMed.com.
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the "Joint Venture"). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
ON BEHALF OF THE BOARD:
(signed) "Peter Bakema"
CEO, President & Director
For further information contact:
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888
This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.